首页> 美国卫生研究院文献>Journal of the Endocrine Society >SAT-LB60 Discordant Biological Parameters of Remission in Acromegaly Do Not Increase the Risk of Hypertension or Diabetes: A Study With the Liege Acromegaly Survey Database
【2h】

SAT-LB60 Discordant Biological Parameters of Remission in Acromegaly Do Not Increase the Risk of Hypertension or Diabetes: A Study With the Liege Acromegaly Survey Database

机译:AcromeGaly中残留的SAT-LB60不安的生物学参数不会增加高血压或糖尿病的风险:与Leege AcromeGaly调查数据库的研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Introduction: Acromegaly is a rare disease due to growth hormone (GH)-secreting pituitary adenoma. GH and IGF-1 levels are usually congruent, indicating either remission or active disease, however a discrepancy between GH and IGF-1 may occur. We aimed to evaluate the outcome of acromegalic comorbidities in patients with congruent GH and/or IGF-1 levels vs discordant biochemical parameters. Methods: Retrospective analysis of the data of 3173 patients from the Liège Acromegaly Survey (LAS) allowed to include 190 patients from 8 tertiary referral centers across Europe, treated by surgery, with available data concerning diabetes mellitus (DM) and hypertension (HT) both at diagnosis and at last follow-up. We recorded for all the patients the number of antihypertensive and antidiabetic drugs used at the first evaluation and at last follow-up. Results: Ninety-nine patients belonged to the REM group (Concordant parameters), sixty-five patients were considered as GHdis and 26 patients were considered as IGF-1dis. At diagnosis, 63 patients (33.1%) had HT and 54 patients had DM (28.4%). There was no statistically significant difference in terms of number of anti-HT and anti-diabetic drugs at diagnosis versus last follow-up (mean duration=7.3+/-4.5years) between all 3 groups. Discussion: The results highlight that the long-term outcome of acromegaly does not tend to be more severe in patients with biochemical discordance in comparison with patients considered as in remission on the basis of concordant biological parameters, suggesting that patients with biochemical discordance do not require a closer follow-up.
机译:介绍:由于生长激素(GH) - 垂体垂体腺瘤,Acromegaly是一种罕见的疾病。 GH和IGF-1级别通常是一致的,表明缓解或活跃疾病,然而可能会发生GH和IGF-1之间的差异。我们旨在评估一致GH和/或IGF-1水平的患者患者患者的癌症患者的结果与不良生物化学参数。方法:回顾性分析3173名止血症患者的数据,允许在欧洲治疗的欧洲8名高等教育中心均允许190名患者,可提供有关糖尿病(DM)和高血压(HT)的可用数据在诊断和最后的后续行动。我们为所有患者记录了第一次评估和最后一次后续的抗高血压和抗糖尿病药物的数量。结果:99名患者属于综合组(协调参数),六十五名患者被认为是GHDIS,26名患者被认为是IGF-1DIS。在诊断中,63名患者(33.1%)具有HT和54名患者DM(28.4%)。在所有3组之间的诊断时,抗HT和抗糖尿病药物数量没有统计学上没有统计学意义差异,并且在所有3组之间进行最后一次随访(平均持续时间= 7.3 +/- 4.5年)。讨论:结果强调,与在辅助生物学参数的患者中,生化不等调患者的长期结果表明,与缓解的患者相比,患者不倾向于更严重,这表明生化不道德的患者不需要更近的随访。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号